JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2005; 46:986-993, doi:10.1016/j.jacc.2004.08.070
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mason, P. J.
Right arrow Articles by Freedman, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mason, P. J.
Right arrow Articles by Freedman, J. E.

Aspirin Resistance and Atherothrombotic Disease

Peter J. Mason, MD, MPH*, Alice K. Jacobs, MD, FACC and Jane E. Freedman, MD, FACC

Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.



View larger version (33K):

[in a new window]
  		Figure 1 Platelet function and mechanisms of antiplatelet therapy. ADP = adenosine diphosphate; Ecs = endothelial cells; Gi = inhibitory G protein; GP = glycoprotein; PG = prostaglandin; P2 = type 2 platelet purinergic receptor; TX = thromboxane; HETE = hydroxyeicosatetraenoic acid; HPETE = hydroperoxyeicosatetraenoic acid.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.